While standard models suffer from context rot as data grows, MIT’s new Recursive Language Model (RLM) framework treats ...

Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.

Here we are on the final stretch to Christmas Day, Christmas joy, Christmas packages and presents and dinners. Shopping is pretty much a done deal, right? I know there’s a thought we could all go out ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Forbes contributors publish independent expert analyses and insights. James Broughel is an economist focused on the economics of regulation. Americans have spent the better part of the last four years ...

Recursion Pharmaceuticals' work could change the way that drugs are developed. Its pipeline features some exciting candidates, and it's partnering with major drugmakers. However, Recursion still needs ...

From A.D.H.D. to anxiety, disorders have risen as the expectations of childhood have changed. Credit...Photo illustration by Ricardo Tomas Supported by By Jia Lynn Yang One of the more bewildering ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...